» Articles » PMID: 21993980

Comparison of 1.5 and 3.0 T for Contrast-enhanced Pulmonary Magnetic Resonance Angiography

Abstract

Objective: In a recent multi-center trial of gadolinium contrast-enhanced magnetic resonance angiography (Gd-MRA) for diagnosis of acute pulmonary embolism (PE), two centers utilized a common MRI platform though at different field strengths (1.5T and 3T) and realized a signal-to-noise gain with the 3T platform. This retrospective analysis investigates this gain in signal-to-noise of pulmonary vascular targets.

Methods: Thirty consecutive pulmonary MRA examinations acquired on a 1.5T system at one institution were compared to 30 consecutive pulmonary MRA examinations acquired on a 3T system at a different institution. Both systems were from the same MRI manufacturer and both used the same Gd-MRA pulse sequence, although there were some protocol adjustments made due to field strength differences. Region-of-interests were manually defined on the main pulmonary artery, 4 pulmonary veins, thoracic aorta, and background lung for objective measurement of signal-to-noise, contrast-to-noise, and bolus timing bias between centers.

Results: The 3T pulmonary MRA protocol achieved higher spatial resolution yet maintained significantly higher signal-to-noise ratio (≥13%, p = 0.03) in the main pulmonary vessels relative to 1.5T. There was no evidence of operator bias in bolus timing or patient hemodynamic differences between groups.

Conclusion: Relative to 1.5T, higher spatial resolution Gd-MRA can be achieved at 3T with a sustained or greater signal-to-noise ratio of enhanced vasculature.

Citing Articles

Value of contrast-enhanced MR angiography for the follow-up of treated brain arteriovenous malformations: systematic review and meta-analysis.

Zhuo Y, Chang J, Chen Y, Wen C, Chen F, Li W Eur Radiol. 2023; 33(10):7139-7148.

PMID: 37148354 DOI: 10.1007/s00330-023-09714-w.


Contrast-enhanced pulmonary MRA for the primary diagnosis of pulmonary embolism: current state of the art and future directions.

Benson D, Schiebler M, Repplinger M, Francois C, Grist T, Reeder S Br J Radiol. 2017; 90(1074):20160901.

PMID: 28306332 PMC: 5602179. DOI: 10.1259/bjr.20160901.


The presurgical T staging of non-small cell lung cancer: efficacy comparison of 64-MDCT and 3.0 T MRI.

Tang W, Wu N, Ouyang H, Huang Y, Liu L, Li M Cancer Imaging. 2015; 15:14.

PMID: 26335333 PMC: 4559286. DOI: 10.1186/s40644-015-0050-4.


Prediction of chemotherapeutic response in bladder cancer using K-means clustering of dynamic contrast-enhanced (DCE)-MRI pharmacokinetic parameters.

Nguyen H, Jia G, Shah Z, Pohar K, Mortazavi A, Zynger D J Magn Reson Imaging. 2014; 41(5):1374-82.

PMID: 24943272 PMC: 4298475. DOI: 10.1002/jmri.24663.


Pulmonary MRA: differentiation of pulmonary embolism from truncation artefact.

Bannas P, Schiebler M, Motosugi U, Francois C, Reeder S, Nagle S Eur Radiol. 2014; 24(8):1942-9.

PMID: 24863886 PMC: 4362685. DOI: 10.1007/s00330-014-3219-5.


References
1.
Erdman W, Peshock R, REDMAN H, Bonte F, Meyerson M, Jayson H . Pulmonary embolism: comparison of MR images with radionuclide and angiographic studies. Radiology. 1994; 190(2):499-508. DOI: 10.1148/radiology.190.2.8284406. View

2.
Stein P, Gottschalk A, Sostman H, Chenevert T, Fowler S, Goodman L . Methods of Prospective Investigation of Pulmonary Embolism Diagnosis III (PIOPED III). Semin Nucl Med. 2009; 38(6):462-70. PMC: 2605689. DOI: 10.1053/j.semnuclmed.2008.06.003. View

3.
Li G, Zeng J, Wang X, Wang R, Li J . [Comparative study of pulmonary magnetic resonance angiography (MRA)]. Hunan Yi Ke Da Xue Xue Bao. 2002; 25(2):173-5. View

4.
Farahani K, Sinha U, Sinha S, Chiu L, Lufkin R . Effect of field strength on susceptibility artifacts in magnetic resonance imaging. Comput Med Imaging Graph. 1990; 14(6):409-13. DOI: 10.1016/0895-6111(90)90040-i. View

5.
Stein P, Chenevert T, Fowler S, Goodman L, Gottschalk A, Hales C . Gadolinium-enhanced magnetic resonance angiography for pulmonary embolism: a multicenter prospective study (PIOPED III). Ann Intern Med. 2010; 152(7):434-43, W142-3. PMC: 3138428. DOI: 10.7326/0003-4819-152-7-201004060-00008. View